Free tool
FAERS Monitor: Utebzi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215960 or its brand name (Utebzi, Tebipenem Pivoxil Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
6
Serious
5
83% of reports
Hospitalization
3
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction2
- nausea2
- anticonvulsant drug level below therapeutic1
- bacterial pyelonephritis1
- blood lactic acid increased1
- cholangitis1
- clostridium difficile infection1
- coagulopathy1
- disseminated intravascular coagulation1
- drug level decreased1
- epilepsy1
- fatigue1
- hypoproteinaemia1
- liver abscess1
- myringitis1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,153 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myringitis | 1 | 48068.8 | 7915.0 | 11,854 |
| bacterial pyelonephritis | 1 | 10474.7 | 1744.6 | 2,610 |
| anticonvulsant drug level below therapeutic | 1 | 4666.3 | 778.6 | 1,164 |
| hypoproteinaemia | 1 | 1848.8 | 308.7 | 461 |
| liver abscess | 1 | 1081.0 | 180.6 | 269 |
| blood lactic acid increased | 1 | 665.6 | 111.2 | 165 |
| cholangitis | 1 | 565.5 | 94.5 | 140 |
| drug level decreased | 1 | 344.4 | 57.5 | 85 |
| disseminated intravascular coagulation | 1 | 249.1 | 41.6 | 61 |
| coagulopathy | 1 | 210.4 | 35.2 | 52 |
| clostridium difficile infection | 1 | 160.6 | 26.8 | 39 |
| epilepsy | 1 | 114.7 | 19.2 | 28 |
| drug interaction | 2 | 44.2 | 14.3 | 47 |
| nausea | 2 | 8.9 | 2.9 | 7 |
| fatigue | 1 | 4.5 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.